SCHEMBL9890694

SCHEMBL9890694

COC(=O)C(O)c1cc(F)ccc1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CHRM3 P20309 5/20 0.40
PTGS1 P23219 4/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
PTGS2 P35354 2/20 0.40
MAPT P10636 2/20 0.40
FABP2 P12104 1/20 0.40
TSHR P16473 1/20 0.40
AKR1C4 P17516 1/20 0.40
ADRA2B P18089 1/20 0.40
HTR2C P28335 1/20 0.40
DRD3 P35462 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40
SLC22A6 Q4U2R8 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890696 0.90 RPS6KB1 (0.41) CHRM3HPGDPSEN1PSEN2APH1B
SCHEMBL9890689 0.89 CHRM3 (0.42) SLC6A4SLC6A3CHRM3PTGS1KMT2A
SCHEMBL9890695 0.84 CHRM3 (0.41) SLC6A4SLC6A3CHRM3KMT2AMEN1
SCHEMBL9890697 0.83 PSEN1 (0.44) CHRM3AKR1C3AKR1C2PSEN1PSEN2
SCHEMBL9890687 0.82 SLC6A4 (0.55) SLC6A4SLC6A3CHRM3PTGS1KMT2A
SCHEMBL9890686 0.82 TUBB4A (0.44) SLC6A4SLC6A3CHRM3HPGD
SCHEMBL1901275 0.82 KMT2A (0.46) KMT2AMEN1MAPTLMNACYP2C9
SCHEMBL2393640 0.81 MAPT (0.40) CHRM3PTGS1KMT2AMEN1PTGS2
SCHEMBL9890690 0.79 CHRM3 (0.43) CHRM3HPGDNR3C2
SCHEMBL30275283 0.77 PTGS1 (0.44) CHRM3PTGS1KMT2AMEN1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SLC6A4 932/4885SLC6A3 724/4885CHRM3 298/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SLC6A4 932/4885SLC6A3 724/4885CHRM3 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.